SG Americas Securities LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 40.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,786 shares of the medical research company’s stock after buying an additional 2,538 shares during the period. SG Americas Securities LLC’s holdings in Bio-Rad Laboratories were worth $1,988,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. First Trust Advisors LP raised its position in Bio-Rad Laboratories by 738.2% in the first quarter. First Trust Advisors LP now owns 24,935 shares of the medical research company’s stock valued at $4,971,000 after buying an additional 21,960 shares during the period. State Board of Administration of Florida Retirement System raised its position in Bio-Rad Laboratories by 4.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 31,359 shares of the medical research company’s stock valued at $6,251,000 after buying an additional 1,362 shares during the period. Syntal Capital Partners LLC raised its position in Bio-Rad Laboratories by 58.8% in the first quarter. Syntal Capital Partners LLC now owns 2,648 shares of the medical research company’s stock valued at $527,000 after buying an additional 981 shares during the period. Great West Life Assurance Co. Can raised its position in Bio-Rad Laboratories by 3.9% in the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock valued at $2,467,000 after buying an additional 469 shares during the period. Finally, Advisory Services Network LLC bought a new position in Bio-Rad Laboratories during the first quarter valued at approximately $115,000. 63.66% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 215.84 on Friday. The firm has a market capitalization of $6.40 billion, a price-to-earnings ratio of 426.56 and a beta of 0.91. The firm has a 50 day moving average price of $226.61 and a 200-day moving average price of $214.37. Bio-Rad Laboratories, Inc. has a 12 month low of $147.68 and a 12 month high of $242.79.

COPYRIGHT VIOLATION WARNING: “SG Americas Securities LLC Buys 2,538 Shares of Bio-Rad Laboratories, Inc. (BIO)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/27/sg-americas-securities-llc-buys-2538-shares-of-bio-rad-laboratories-inc-bio.html.

Several research firms recently commented on BIO. Zacks Investment Research lowered Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 target price on the stock. Finally, BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $228.80.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the SEC, which is available through this link. 28.29% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.